Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Array Biopharma Inc (NASDAQ:ARRY)

8.66
BATS BZX Real-Time Price
As of 2:45pm ET
 -0.07 / -0.80%
Today’s Change
2.38
Today|||52-Week Range
8.97
+105.21%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Array BioPharma, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, ONT-380 (ARRY-380), ARRY-797, Ipatasertib, Motolimod, Danoprevir, ARRy-614, GDC-0994, and LOXO-101. Its drugs focuses on the treatment of cancer and inflammatory diseases. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Contact Information

Array BioPharma, Inc.
3200 Walnut Street
Boulder Colorado 80301
P:(303) 381-6600
Investor Relations:
(303) 386-1193

Employees

Shareholders

Other institutional57.60%
Mutual fund holders36.77%
Individual stakeholders22.78%

Top Executives

Ron SquarerChief Executive Officer & Director
Andrew R. RobbinsChief Operating Officer
Jason HaddockChief Financial Officer
Nicholas A. SaccomanoChief Scientific Officer
Victor SandorChief Medical Officer